Serum Bactericidal Activity of the Methoxyfluoroquinolones Gatifloxacin and Moxifloxacin against Clinical Isolates of Staphylococcus Species: Are the Susceptibility Breakpoints Too High?

Clinical Infectious Diseases

Volumn 37, Issue 10, 2003, Pages 1392-1395

  Stein, Gary E ^a   Schooley, Sharon ^a   Kaatz, Glenn W ^b,c  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GATIFLOXACIN; MOXIFLOXACIN; QUINOLONE DERIVATIVE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; SERUM BACTERICIDAL ACTIVITY; STAPHYLOCOCCUS AUREUS;

ADULT; AZA COMPOUNDS; BLOOD BACTERICIDAL ACTIVITY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; QUINOLINES; SERUM BACTERICIDAL TEST; STAPHYLOCOCCUS;

EID: 0242468541     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/379518     Document Type: Article

References (14)

1. Fung-Tomc J, Minassian B, Kolef B, Washo T, Huczko E, Bonner D. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin. J Antimicrob Chemother 2000; 45:437-46.
2. Barry AL, Fuchs PC, Brown SD. Antibacterial activity of moxifloxacin (BAY 12-8039) against aerobic clinical isolates, and provisional criteria for disk susceptibility tests. Eur J Clin Microbiol Infect Dis 1999; 18: 305-9.
3. Wright DH, Brown GH, Peterson ML, Rotschafer JC. Application of fuoroquinolone pharmacodynamics. J Antimicrob Chemother 2000; 46:669-83.
4. Xuan D, Zhong M, Mattoes H, et al. Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model. Antimicrob Agents Chemother 2001; 45:794-9.
5. Kaatz GW, Seo SM. Mechanisms of fluoroquinolone resistance in genetically related strains of Staphylococcus aureus. Antimicrob Agents Chemother 1997; 41:2733-7.
6. Stein G, Schooley S, Tyrrell KL. Bactericidal activities of methoxyfluoroquinolones gatifloxacin and moxifloxacin against aerobic and anaerobic respiratory pathogens in serum. Antimicrob Agents Chemother 2003; 47:1308-12.
7. Lutsar I, Friedland IR, Wubbel L, et al. Pharmacodynamics of gatifloxacin in cerebrospinal fluid and experimental cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1998; 42:2650-5.
8. t /MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model. J Antimicrob Chemother 2003; 51:905-11.
9. Firsov AA, Lubenko IY, Vostrov SN, Kononenko OV, Zinner SH, Portnoy YA. Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. J Antimicrob Chemother 2000; 46:725-32.
10. Vostrov SN, Konoenko OV, Lubenko IY, Zinner SH, Firsov AA. Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio. Antimicrob Agents Chemother 2000; 44:879-84.
11. Andes D, Craig WA. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. Antimicrob Agents Chemother 2002; 46:1665-70.
12. Lister PD. Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model. Clin Infect Dis 2001; 32:S33-8.
13. Wright DH, Gunderson BW, Hovde LB, Ross GH, Ibrahim KH, Rotschafer JC. Comparative pharmacokinetics of three newer fluoroquinolones versus six strains of staphylococci in an in vitro model under aerobic and anaerobic conditions. Antimicrob Agents Chemother 2002; 46:1561-3.
14. MacGowan AP, Rogers CA, Holt HA, Bowker KE. Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 2003; 47:1088-95.